NEW YORK, May 27, 2026, 08:14 EDT
Soligenix Inc. shares nearly doubled in pre-market trading on Wednesday after the low-priced biotech tied its ThermoVax vaccine-stabilization technology to the Bundibugyo Ebola outbreak in Congo and Uganda, extending a sharp gain from Tuesday’s regular session. Google Finance showed SNGX at $1.00 pre-market, up 94.6% from a $0.51 close; a market-data feed listed the latest regular-market price at $0.513.
The move matters now because the outbreak has become a global-alert event. The World Health Organization on May 17 declared the epidemic a Public Health Emergency of International Concern, or PHEIC, its highest alert under international health rules, while saying it did not meet the bar for a pandemic emergency.
Case counts have kept rising. The European Centre for Disease Prevention and Control said its page was updated at 26 May 17:40 and cited DRC health ministry figures showing 105 confirmed cases, including 10 deaths, and 906 suspected cases, including 223 deaths, in three DRC provinces; Uganda had seven confirmed cases, including one death.
For investors, the market gap is the vaccine gap. The U.S. CDC said the risk of spread to the United States was low, but also said there is no FDA-licensed or authorized vaccine to protect against Bundibugyo virus infection and no FDA-approved or authorized treatment for the disease.
Soligenix said Tuesday that the outbreak would require new vaccine formulation efforts and pointed to previous work with Axel Lehrer, a professor at the University of Hawaiʻi at Mānoa, on filovirus vaccines. Lehrer said adequate funding could allow the group to “rapidly advance development,” while Soligenix CEO Christopher Schaber called ThermoVax a “well-established thermostabilization strategy.” A subunit vaccine uses selected pieces of a virus, rather than the whole virus, to train an immune response. Soligenix Investor Relations
The competitive backdrop is not a clean race against an approved Bundibugyo product. WHO says the licensed Ebola vaccines it lists — Merck’s Ervebo and the two-dose Zabdeno/Mvabea regimen — are for disease caused by Zaire ebolavirus, a different species.
Outside experts remain cautious. Prof Emma Thompson, director of the MRC–University of Glasgow Centre for Virus Research, said “further urgent research is required,” and Gavi noted that candidate Bundibugyo vaccine timelines range from two-to-three months for one production effort to six-to-nine months for another, with gaps in animal or human data. Gavi
The outbreak also pushed into U.S. market screens after Reuters reported Tuesday that the CDC had begun seeking staff volunteers to help with Ebola screening at U.S. entry points as the response expanded.
But the rally rests on an early platform claim, not an order or an approved product. Soligenix reported no revenue for the first quarter, a $2.8 million net loss and about $6.0 million in cash, and said its Phase 3 HyBryte trial — a late-stage human study — had been recommended to halt for futility, meaning monitors saw too little chance of success to keep it running. A separate SEC filing showed the company issued 4.3 million shares from April 1 to May 1 through an at-the-market program, a way to sell stock into the market over time, at a weighted-average fair value of $0.50.
The immediate test is whether pre-market demand holds once regular trading opens. The slower one is whether Soligenix can turn heat-stable vaccine know-how into financed, testable Bundibugyo work while public-health agencies weigh other vaccine options.
